Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

Exclusion Criteria

• •1. Liver transplant (LTx) for autoimmune disease, including autoimmune hepatitis or primary sclerosing cholangitis
• •2. LTx for hepatitis B or hepatitis C
• •3. Recipient of any other organ transplant or liver re-transplant, except for patients who have a repeat LTx within 30 days of first LTx who are eligible for enrollment
• •4. \>=50 percent dose increase in tacrolimus within 12 months of enrollment
• •5. Discontinued a second Immunosuppression (IS) agent within 12 months of enrollment
• •6. Systemic illness requiring chronic or recurrent use of IS for which there is a risk of reactivation if tacrolimus is reduced
• •7. Use of medication to treat systemic conditions which in the judgement of the investigator could influence results of the study
• •8. Active or chronic infection requiring treatment
• •9. Inability or unwillingness to comply with the study protocol
• •10. Use of investigational drug within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of enrollment
• •11. Has any condition that, in the opinion of the investigator, will interfere with safe participation in the trial